Altair Therapeutics Receives $17,000,000 New Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1a36ca1d-10d3-48f5-9dda-6c9dd154ade4&Preview=1
Date
11/12/2009
Company Name
Altair Therapeutics
Mailing Address
12555 High Bluff Drive San Diego, CA 92130
Company Description
Altair is building a dedicated team, combining antisense drug discovery expertise with respiratory drug development expertise, to focus solely on the development and commercialization of antisense drugs for the treatment of asthma and other respiratory conditions.
Website
http://www.altairtherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$17,000,000
Transaction Round
Undisclosed
Proceeds Purposes
Altair Therapeutics will use the funding to complete phase 2a trials for its lead product, inhaled AIR645 and advance research and development in new target programs.
M&A Terms
Venture Investor
Domain Associates
Venture Investor
Thomas, McNerny & Partners
Venture Investor
Forward Ventures
Venture Investor
Isis Pharmaceuticals
Venture Investor
Undisclosed